The antibody mAb806 is used to treat glioblastoma, although its mechanism of action has been unknown until now.
The study, published in the journal PNAS, paves the way to extend treatment with mAb806 to more types of tumours and to the development of more personalised therapies.
Glioblastoma is an incurable type of brain tumour that is frequently associated with mutations in the epidermal growth factor receptor (EGFR). The main EGFR mutation found in glioblastomas, called EGFRvIII, is treated with the antibody mAb806, a drug developed by the Ludwig Institute for Cancer Research (US) about 20 years ago, but whose mechanism of action was unknown. In collaboration with the University of Stockholm (Sweden) and the University of California San Diego (USA), researchers at the Institute for Research in Biomedicine (IRB Barcelona) have unravelled how this antibody acts on mutated EGFR, thus dramatically extending its application to virtually any glioblastoma mutations.
Published in the journal PNAS, the study paves the way for new treatments for cancer. The results of the work indicate that, in contrast to what was previously believed, mAb806 could be used to treat many tumours that carry EGFR mutations and not only for a specific mutation.
Furthermore, the scientists have demonstrated that even when EGFR is not mutated, it can be treated in order to make it susceptible to mAb806 therapy. “This finding lays the rational basis for anti-EGFR combination treatments with antibodies and kinase inhibitors, instead of “blind testing” them, as has been done until now,” says Modesto Orozco, head of the Molecular Modelling and Bioinformatics Lab at IRB Barcelona and senior professor of the Faculty of Chemistry at the University of Barcelona.
More than 100 mutations in EGFR have been described to give rise to glioblastoma. By means of computational simulation, Laura Orellana, first author of the study who began this project during her PhD at IRB Barcelona and is now a researcher at Stockholm University, discovered that the mutations studied induced a similar change in the shape of the receptor. “Surprisingly, this change in EGFR matches the shape recognised by mAb806, but this hadn’t previously been observed experimentally,” she comments.
Previous studies had reported that mAb806 recognises a region of EGFR that is normally hidden. In certain tumours carrying EGFRvIII, half of the receptor has been removed, so that this region becomes accessible, thereby allowing the therapeutic use of the antibody. The researchers have now demonstrated that many different mutations on EGFR change the shape of the receptor, allowing mAb806 to detect this “hidden” region.
These changes in the shape of EGFR affect its activation. While analysing computational simulations of EGFR, Orellana discovered that while a part of the receptor is “eliminated" in EGFRvIII, in other mutants this same part is “displaced”, with the same objective of activating the receptor.
“This surprising finding provides a rational basis to explain why distinct mutations in glioblastoma respond to drugs in a similar manner,” explains Orellana. “Mutations that are seemingly different are in fact equivalent and have the same effect on the receptor, driving the formation of a tumour”.
In collaboration with the Ludwig Institute for Cancer Research and the University of California San Diego, the researchers validated this computational hypothesis using cell and animal models, which confirmed the therapeutic potential of mAb806a.
“Given the numerous clinical assays underway with mAb806 worldwide, the translation of these results into clinical practice will be much faster than normal, and treatment with this antibody is expected to be suitable for many types of tumour that carry similar mutations, such as tumours found in the colon, breast and skin,” says Orozco.
The study is a collaboration between IRB Barcelona, the Royal Institute of Technology (KTH) of Stockholm, the University of Stockholm, the Ludwig Institute for Cancer Research, the University of California San Diego, the Barcelona Supercomputing Center, the University of Lisbon and the Centre de Biochimie Structurale (CNRS).
The study was funded by the Ministry of Science, Innovation and Universities, ICREA, the Catalan Government, the European Research Council, Vetenskapsrådet and the Swedish e-Science Research Center (E.L.).
Laura Orellana, Amy H. Thorne, Rafael Lema, Johan Gustavsson, Alison D. Parisian, Adam Hospital, Tiago N. Cordeiro, Pau Bernadó, Andrew M. Scott, Isabelle Brun-Heath, Erik Lindahl, Webster K. Cavenee, Frank Furnari and Modesto Orozco.
PNAS (2019) doi:10.1073/pnas.1821442116.
About IRB Barcelona
Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 27 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).